DOR BioPharma Provides Update on orBec European Regulatory and Development Strategy
                   
pharmiweb.co.uk     May 22, 2008            

DOR Enters into Letter of Intent with IDIS for Named Patient Access of orBec® in Europe EWING, NJ - DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments, serious... [read full story]                

Add a comment to the article
Type the code shown

View all news articles about:

- Related Topics

View other selected articles:

                   

DOR BioPharma Announces Named Patient Access Program for orBec(R) in Singapore and Malaysia in...

redorbit.com     Jul 18, 2008   1 related          

Patient Access Program (NPAP) for orBec(R) to patients suffering from acute gastrointestinal Graft-versus-Host disease (GI GVHD) in Singapore and Malaysia. Steward Cross and DOR will share revenues generated by sales of...                

comments

                   

DOR BioPharma Announces Named Patient Access Program for orBec(R) in Singapore and Malaysia in...

yahoo.com     Jul 18, 2008   11 related          

EWING, NJ--(MARKET WIRE)--Jul 18, 2008 -- News ) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal...                

comments

                   

DOR BioPharma Announces Collaboration With Numoda Corporation for the Execution of Confirmatory,...

redorbit.com     Jun 30, 2008   8 related          

gastrointestinal Graft-versus-Host disease (GI GVHD). Collaborating with Numoda will allow DOR to take full advantage of a comprehensive scope of services including using their robust industry benchmarking capabilities to...                

comments

Collaborations Between Biotechnology Companies And Government/Nonprofit Institutions: Feb. 29 -...

tmcnet.com     Jun 2, 2008          

Company* (Country; Symbol) University/ Nonprofit @ Type Of Agreement Details (Date) 3M Drug Delivery Systems Infectious Disease Research Institute Nonexclusive license agreement To support vaccine? research for humanitarian efforts...                

comments